Sustained-Release Bupropion for Smoking Cessation in a Chinese Sample: A Double-Blind, Placebo-Controlled Randomized Trial

Bupropion is a first-line pharmacological aid for smoking cessation; however, no clinical trials have been conducted in a Chinese population. We enrolled 248 smokers in a hospital-based, randomized, smoking cessation trial conducted at four outpatient centers in Beijing. A total of 123 participants...

Full description

Saved in:
Bibliographic Details
Published in:Nicotine & tobacco research 2013-02, Vol.15 (2), p.320-325
Main Authors: Sheng, Li-xia, Tang, Yi-lang, Jiang, Zuo-ning, Yao, Chong-hua, Gao, Jun-yu, Xu, Guo-Zhu, Tong, Xin-yuan
Format: Article
Language:English
Subjects:
Adult
Bupropion - therapeutic use
China
Double-Blind Method
Female
Humans
Male
Middle Aged
ORIGINAL INVESTIGATIONS
Placebos
Smoking Cessation
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bupropion is a first-line pharmacological aid for smoking cessation; however, no clinical trials have been conducted in a Chinese population. We enrolled 248 smokers in a hospital-based, randomized, smoking cessation trial conducted at four outpatient centers in Beijing. A total of 123 participants received an 8-week course of sustained-release bupropion (Bup-SR) and 125 participants received 8 weeks of placebo. All participants received brief education and counseling on smoking cessation. We determined rates of abstinence and smoking reduction based on chemical verification and self-report at 8 and 12 weeks. At the end of the medication treatment (8 weeks) and at the end of the trial (12 weeks), the abstinence rates for Bup-SR were 29.3% and 39.8%, respectively, and 10.4% and 8.0% for placebo, respectively (both p < .001). Bup-SR was also superior to placebo in reducing cigarettes per day and urinary cotinine levels. Bup-SR is efficacious for smoking cessation in healthy Chinese patients treated in the outpatient setting. It is well tolerated with a few mild side effects.
ISSN:1462-2203
1469-994X
DOI:10.1093/ntr/nts124